S100 proteins, a family of calcium-binding proteins, implicate in a variety of cellular behaviors such as signaling, growth, differentiation, and motility.
6 S100A proteins participate in inflammation-related corneal neovascularization (CNV). For instance, S100A8 or S100A9 is viewed as a target for the treatment of diseases involving CNV.
7 Elevation of S100A8 and S100A9 is observed in some inflammatory ocular diseases, including xerophthalmia, meibomian gland dysfunction, and CNV.
8 As a major member of the S100 family, S100A4 protein is localized in the keratocyte phenotypes that emerge in corneal stromal tissues recovering from injury.
9 S100A4 is also a potent protein that triggers inflammation and production of cytokines and growth factors under various pathologic conditions.
10 Strikingly, our previous study has demonstrated that S100A4 silencing functions as a suppressor in CNV following alkali burn in vivo.
11 S100A4 is also introduced as a therapeutic target for neurodegeneration diseases, which may be a vital mediator for central nervous system injury.
12 Activation of Akt proteins may be a significant therapeutic approach for corneal wound healing, along with the healing of other tissues such as the skin.
13 An activated PI3K/Akt signaling pathway caused by phosphatase and tensin homologue deleted on chromosome 10 may be associated with enhanced cell migration and wound healing.
14 Activation of the the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway is engaged in S100A4-mediated migration of colorectal cancer cells,
15 which may raise a potential mechanism involving the corneal repair following alkali burn. In view of this, our study aimed to examine the effect of S100A4 on corneal alkali burn in a rabbit model and a corneal stromal cell (rCSC) model, with the aim to explore the potential therapies for alkali-burned corneas.